Merck & Co. Inc. (MRK)

Management raised its full-year forecast, but the market seems to be asking for more than a higher target.

RAS mutations fuel nearly a third of all cancers, and one biotech has quietly built the deepest late-stage pipeline targeting them. Now the biggest names in pharma are circling, and the math on who ca...

With all eyes locked on this morning's CPI release and the Strait of Hormuz nearly shut down, Wall Street analysts are already repositioning across hospitality, pharma, and tech before the market even...

Infinimmune is targeting first-in-human studies with its longer-lasting monoclonal antibodies in 2027.

This healthcare giant is on a serious run, but with the stock trading at a peak, investors must decide if the powerful business engine has more fuel or if the price has already burned it all.